Comparison

PKM2 Antibody

Item no. E90268
Manufacturer Enogene
Amount 100 ul
Quantity options 100 ug/100 ul 50 ug/50 ul 100 ug/100 ul 50 ug/50 ul 100 ug/100 ul 100 ug/100 ul 50 ug/50 ul 100 ug/100 ul 100 ul 100 ul
Category
Type Antibody
Applications WB, IHC
Specific against Human (Homo sapiens), Mouse (Murine, Mus musculus), Rat (Rattus norvegicus)
Host Rabbit
ECLASS 10.1 32160702
ECLASS 11.0 32160702
UNSPSC 12352203
Alias PKM2 , TCB, PK3, PKM2 pyruvate kinase, muscle, CTHBP, PK2
Available
Manufacturer - Conjugate / Tag
This antibody is also available with the following conjugates:
AF350, AF405L, AF405M, AF405S, AF488, AF514, AF532, AF546, AF555, AF568, AF594, AF610, AF635, AF647, AF680, AF700, AF750, AF790, APC, AP, Biotin, Cy3, Cy5.5, Cy5, Cy7, FITC, HRP, PE, Magnetic beads (1 um, 2.8 um, 3 um, 4.5 um, 5 um, 10 um, 15 um, 20 um, 30 um, or different size option)
Please contact sales@hoelzel.de for pricing and availability.
Storage Conditions
Store at -20C or -80oC. Avoid freeze / thaw cycles. Buffer: PBS with 0.02% sodium azide, 50% glycerol, pH7.3.
Molecular Weight
58kDa
Immunogen
Recombinant Proteinof human PKM2
Purification
Affinity purification
Research Area
Autophagy antibody, Cancer, Cardiovascular, Cell Biology, Epigenetics and Nuclear Signaling, Developmental Biologys, Immunology, Drug Discovery Products, Metabolism, Neuroscience, Signal Transduction, Stem Cells
Background
Pyruvate kinase, a glycolytic enzyme, catalyses the conversion of phosphoenolpyruvate to pyruvate. In mammals, the M1 isoform (PKM1) is expressed in most adult tissues (1). The M2 isoform (PKM2), an alternatively-spliced variant of M1, is expressed during embryonic development (1). Studies found that cancer cells exclusively express PKM2 (1-3). PKM2 is shown to be essential for aerobic glycolysis in tumors (Warburg effect) (1). When the M2 isoform is switched to the M1 isoform, aerobic glycolysis is reduced and oxidative phosphorylation is increased in cancer cells (1). These cells also show decreased tumorigenicity in mouse xenografts (1). Recent studies show that the oncogenic forms of FGFR1 directly phosphorylate Tyr105 of PKM2 and thereby inhibit the formation of active tetrameric PKM2 (4). A PKM2 mutant found in cancer cells, in which Tyr105 is replaced by phenylalanine, leads to reduced cell proliferation in hypoxia and tumor growth in xenografts in nude mice (4). These findings suggest that the phosphorylation at Tyr105 is a critical switch for the metabolism in cancer cells that promotes tumor growth (4).
CiteID
EN0124964

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Amount: 100 ul
Available: In stock
available

Compare

Add to wishlist

Get an offer

Request delivery time

Ask a technical question

Submit a bulk request

Questions about this Product?
 
Close